Drupal.behaviors.print = function(context) {window.print();window.close();}>
Cancer Genetics Revises IPO Filing, Targets $29.3M in Proceeds
February 13, 2013
Cancer Genetics Revises IPO Filing, Targets $29.3M in Proceeds
By
a GenomeWeb staff reporter
Full-text access for registered users only.
Existing users
login here
.
New to GenomeWeb?
Register here
quickly for free access.
Related Stories
Underwriters Exercise Over-allotment Option on Cancer Genetics IPO
April 8, 2013 / GenomeWeb Daily News
Cancer Genetics Prices IPO; Expects $6M in Proceeds
April 5, 2013 / GenomeWeb Daily News
Cancer Genetics Partners with Gilead on CLL Clinical Trials; Revises Expected Proceeds from IPO
March 12, 2013 / GenomeWeb Daily News
Cancer Genetics Lowers Expected Proceeds from IPO, Increases 2012 Revenues
March 4, 2013 / GenomeWeb Daily News
Cancer Genetics Again Lowers Expected Proceeds from IPO to $23.5M
February 14, 2013 / GenomeWeb Daily News